Description: Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California. On October 13, 2024, Notable Labs, Ltd. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with Notable Labs, Inc.
Home Page: www.notablelabs.com
320 Hatch Drive
Foster City,
CA
94404
United States
Phone:
415-851-2410
Officers
| Name | Title |
|---|---|
| Mr. Scott Alan McPherson CFE, CPA, CVA | Chief Financial Officer |
| Dr. Joseph P. Wagner Ph.D. | Chief Scientific Officer |
| Ms. Kaile Zagger | Interim CEO & Chief Restructuring Officer |
| Dr. Glenn C. Michelson M.D. | Chief Medical Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |